

Clinical trials of darusentan

TrialResults-center www.trialresultscenter.org

1 hypertension

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---|
| darusentan vs placebo | | | |
| DORADO-AC n=NA follow-up: | - | - | |
| DORADO , 2009 [NCT00330369] n=247/132 follow-up: 14 weeks | darusentan 50 mg, 100 mg or 300 mg versus placebo | patients with treatment-resistant hypertension | Parallel groups double blind North and South America, Europe, New Zealand, Australia |

More details and results :

- anti hypertensive agents for hypertension in patients with treatment-resistant hypertension at <http://www.trialresultscenter.org/go-Q374>

References

DORADO-AC, :

DORADO, 2009:

Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1423-31 [19748665]